The Star Wars Biotech: Corindus Vascular Robotics

Written by GSCR Staff   
Wednesday, 16 December 2015 08:02

In case you have not heard, Star Wars: The Force Awakens comes out Friday. We mentioned how the movie could ‘dominate’ stocks, but we were speaking more about Hollywood and Disney (NYSE- DIS) in particular. With the market turmoil and imminent Fed announcement we thought we would look for value in the microcapsector, biotech.

The chart below illustrates and approximate head and shoulders pattern that has emerged for Corindus Vascular Robotics, Inc. (NYSE – CVRS - $3.03) over the last six months. Now may be time for a trade.

CVRS6-Month Chart

(Source: www.otcmarkets.com)

MM.12.16.15.CVRS-6mo

Corindus Vascular is an interesting Company that is a global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The Company's FDA cleared CorPath System is the first medical device that offers interventional cardiologists PCI procedure control from a radiation protective interventional cockpit. This all sounds very Star Wars to us, but this is a robotic system that facilitates stent placement for percutaneous coronary intervention procedures by allowing a physician to measure, manipulate, and advance devices with robotic precision.

The Company is still in the development stage so EPS and some other metrics may not apply. Another technical metric that may indicate a buy is the short float of just 7%. Also, Corindus Vascular had $50 million cash as of the end of 3Q15 with just $8.6 million of debt at that time. Finally, the Company just received the final FDA approval for the CorPath System in October which is a unique product in the industry. Deal flow should be in the pipeline and will facilitate big pops next year.

We believe the healthcare industry will remain an important investment category in 2016. CVRS offers a niche product with a cheap price at the current time. Look for a climb back to $4 sometime in 2Q16 or sooner.

Have a great day!

Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.

It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. Please view the company’s individual disclosures for each engagement, which can be found in each company-specific report. All information contained in this blog, newsletter and in our reports were provided by the Companies or generated from our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small CapResearch blog, report, note, or newsletter is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.

This blog does not take into account the investment objectives, financial situation, or particular needs of any particular person. This blog does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA or with any state securities regulatory authority.

ALL INFORMATION IN THIS BLOG, REPORT OR NEWSLETTER IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLECONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS   INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLECONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: www.goldmanresearch.com

Add comment
  • No comments found